Clear Harbor Asset Management LLC Buys 3,006 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Clear Harbor Asset Management LLC raised its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 124.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 5,421 shares of the biopharmaceutical company’s stock after buying an additional 3,006 shares during the quarter. Clear Harbor Asset Management LLC’s holdings in Regeneron Pharmaceuticals were worth $3,862,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Aspiriant LLC lifted its holdings in Regeneron Pharmaceuticals by 14.5% during the 4th quarter. Aspiriant LLC now owns 387 shares of the biopharmaceutical company’s stock valued at $276,000 after purchasing an additional 49 shares during the last quarter. Crossmark Global Holdings Inc. boosted its position in shares of Regeneron Pharmaceuticals by 3.6% during the 4th quarter. Crossmark Global Holdings Inc. now owns 2,654 shares of the biopharmaceutical company’s stock worth $1,890,000 after acquiring an additional 92 shares in the last quarter. Cove Private Wealth LLC bought a new position in shares of Regeneron Pharmaceuticals in the 4th quarter valued at $313,000. Willner & Heller LLC boosted its stake in shares of Regeneron Pharmaceuticals by 3.9% in the 4th quarter. Willner & Heller LLC now owns 399 shares of the biopharmaceutical company’s stock valued at $284,000 after purchasing an additional 15 shares in the last quarter. Finally, Mechanics Bank Trust Department bought a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter worth $288,000. 83.31% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on REGN. Evercore ISI lowered their target price on shares of Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating on the stock in a report on Thursday, October 24th. JPMorgan Chase & Co. cut their price target on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an “overweight” rating on the stock in a report on Thursday, October 24th. Canaccord Genuity Group initiated coverage on shares of Regeneron Pharmaceuticals in a report on Tuesday, December 17th. They set a “hold” rating and a $165.00 price objective for the company. Leerink Partners restated a “market perform” rating and issued a $1,077.00 target price (down from $1,175.00) on shares of Regeneron Pharmaceuticals in a research note on Tuesday, September 24th. Finally, Leerink Partnrs downgraded shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 24th. One investment analyst has rated the stock with a sell rating, seven have given a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Regeneron Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $1,015.38.

Regeneron Pharmaceuticals Trading Down 1.7 %

Shares of Regeneron Pharmaceuticals stock opened at $681.58 on Tuesday. The business has a 50-day moving average price of $738.60 and a 200-day moving average price of $948.80. Regeneron Pharmaceuticals, Inc. has a twelve month low of $666.25 and a twelve month high of $1,211.20. The firm has a market cap of $74.90 billion, a price-to-earnings ratio of 16.87, a PEG ratio of 1.61 and a beta of 0.10. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.